Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s...
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
About this item
Full title
Author / Creator
Publisher
England: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer's disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and randomized 2:1 to either increase their donepezil dose to 23 mg/d...
Alternative Titles
Full title
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_6f07624f29f04534ac2934a401407e95
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_6f07624f29f04534ac2934a401407e95
Other Identifiers
ISSN
1756-0500
E-ISSN
1756-0500
DOI
10.1186/1756-0500-5-283
